the product in the database has an inactive status
indications:
Chronic constipation. Encephalopathy in the course of hepatic failure (pre-coma and hepatic coma).
Composition:
5 ml of syrup contains 2.5 g of lactulose. The preparation contains sorbitol 8 mg in 5 ml of syrup.
Action:
Lactulose consists of a molecule of galactose and fructose. In the large intestine, it is degraded mainly to lactic acid, from which, as a result of transformation, short-chain fatty acids are formed, which are absorbed by the colon epithelium. The absorption of sodium and water and the secretion of bicarbonates is increased, which causes an increase in the osmotic pressure and slight acidification of the contents of the large intestine, and thus an increase in the water content in the stool and its relaxation. The product also leads to a decrease in the concentration of ammonia in the blood, which is important in patients with portal hypertension and hepatic encephalopathy. Lactulose is slightly absorbed from the gastrointestinal tract. Approx. 99% of the lactulose dose is metabolised by intestinal bacteria, mainlyLactobacillus spp. andBifidobacterium spp. for organic acids and gases. Small amounts of unchanged lactulose are present in the urine.
Contraindications:
Hypersensitivity to lactulose or other components of the preparation. Bowel obstruction. Increased blood galactose concentration. Lactose intolerance.
Precautions:
It should not be used in patients with rare hereditary problems of galactose or fructose intolerance, lactase deficiency (Lapp type) or malabsorption of glucose-galactose.
Pregnancy and lactation:
Exercise caution when administering the preparation to pregnant women. There is no information on the use during breastfeeding.
Side effects:
During constipation, in the initial period of use observed: mild, transient bloating, abdominal pain, nausea. Very rare: diarrhea, which disappears after 5 hours from the beginning of treatment. In high doses in hepatic encephalopathy, in addition: hypokalemia, hyponatremia, isolated cases of intestinal vesicular dysmenasia.
Dosage:
Orally. Adults: Chronic constipation: initial dose: 20-40 ml per day in 1-2 doses. After obtaining the effect, the dose should be individually determined according to the patient's needs. In liver failure, pre-coma or hepatic coma: 120-240 ml in 3-4 doses per day. Dosage should be determined individually, changing them every 1-2 days, so that the number of bowel movements per day was 2-3. Children: Chronic constipation: 5-15 ml (1-3 teaspoons) per day. Initially, infants - 2.5 ml, children up to 3 years - 5 ml, over 3 years - 15 ml per day. The dose can then be gradually increased every 3 days until normal bowel movements are achieved. When the abdominal bloating occurs, reduce the dose to tolerated by the child. Add syrup after dilution with water or fruit juice.
(C)
